Drug Trial Radar · NCT00309621
Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Apr 2006
Primary completion
Apr 2007
Study completion May 2007
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin. The study aims to investigate the safety and efficacy of the medication when given over a period of 6 months.
Conditions
- Hand Dermatoses
Interventions
alitretinoinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety:
- Adverse Events
- Safety Laboratory
- Radiological investigations (bone density, x-ray)
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Québec, Canada
Site not named
Edmonton, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Winnipeg, Manitoba, Canada
Site not named
Hawkesbury, Ontario, Canada
Site not named
London, Ontario, Canada
Site not named
Markham, Ontario, Canada
Site not named
Oakville, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Sheerbroke, Quebec, Canada
Site not named
Berlin, Germany
Site not named
Berlin, Germany
Site not named
Cologne, Germany
Site not named
Frankfurt, Germany
Site not named
Hamburg, Germany
Site not named
Hamburg, Germany
Site not named
Hamburg, Germany
Abt. Klinische Sozialmedizin
Heidelberg, Germany
Site not named
Ibbenbueren, Germany
Site not named
Lübeck, Germany
Site not named
Mönchengladbach, Germany
Site not named
München, Germany
Site not named
Münster, Germany
Site not named
Osnabrück, Germany
Site not named
Potsdam, Germany
Site not named
Viersen, Germany
Site not named
Wuppertal, Germany
Site not named
Gdansk, Poland
Site not named
Krakow, Poland
Site not named
Lublin, Poland
Site not named
Opole, Poland
Site not named
Szcecin, Poland
Site not named
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.